Knight Therapeutics Inc (GUD) Price Target Cut to C$10.50 by Analysts at Scotiabank

Knight Therapeutics Inc (TSE:GUD) had its target price lowered by equities researchers at Scotiabank from C$11.00 to C$10.50 in a research note issued on Friday, May 12th. The firm currently has an “outperform” rating on the stock. Scotiabank’s price target suggests a potential upside of 8.47% from the stock’s previous close.

A number of other research analysts have also recently commented on GUD. TD Securities reissued a “buy” rating and issued a C$12.50 target price on shares of Knight Therapeutics in a research note on Thursday, February 9th. CIBC dropped their target price on shares of Knight Therapeutics from C$13.00 to C$9.80 in a report on Friday, January 13th. Finally, National Bank Financial raised their price objective on shares of Knight Therapeutics from C$11.00 to C$11.75 in a report on Wednesday, March 15th. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Knight Therapeutics presently has an average rating of “Buy” and a consensus target price of C$11.06.

Knight Therapeutics (TSE GUD) traded up 1.57% during midday trading on Friday, reaching $9.68. The company had a trading volume of 155,514 shares. The company’s 50-day moving average is $10.12 and its 200 day moving average is $10.29. Knight Therapeutics has a 52-week low of $7.88 and a 52-week high of $11.03. The company has a market cap of $1.38 billion and a PE ratio of 54.38.

WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

What are top analysts saying about Knight Therapeutics Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Knight Therapeutics Inc and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit